Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Swiss National Bank

Swiss National Bank increased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 12.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 151,900 shares of the company's stock after buying an additional 17,200 shares during the period. Swiss National Bank owned 0.19% of Travere Therapeutics worth $2,646,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TVTX. Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics in the fourth quarter valued at approximately $214,000. US Bancorp DE grew its stake in Travere Therapeutics by 323.4% in the 4th quarter. US Bancorp DE now owns 31,795 shares of the company's stock valued at $554,000 after acquiring an additional 24,286 shares during the period. FMR LLC increased its holdings in Travere Therapeutics by 27.5% in the 3rd quarter. FMR LLC now owns 147,416 shares of the company's stock worth $2,062,000 after acquiring an additional 31,772 shares in the last quarter. Two Sigma Advisers LP increased its holdings in Travere Therapeutics by 30.2% in the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company's stock worth $10,078,000 after acquiring an additional 167,100 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Travere Therapeutics by 3.9% during the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company's stock worth $24,222,000 after acquiring an additional 64,744 shares during the period.

Insiders Place Their Bets

In other Travere Therapeutics news, CEO Eric M. Dube sold 11,375 shares of the company's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the sale, the chief executive officer now owns 419,173 shares in the company, valued at $10,076,918.92. This represents a 2.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP William E. Rote sold 5,200 shares of Travere Therapeutics stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the transaction, the senior vice president now owns 98,519 shares of the company's stock, valued at $2,318,152.07. The trade was a 5.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 191,335 shares of company stock worth $4,194,712 in the last ninety days. 3.75% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on TVTX shares. Evercore ISI boosted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Citigroup lifted their price objective on Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Monday, February 24th. JPMorgan Chase & Co. increased their target price on Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Finally, HC Wainwright upped their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $30.62.

Travere Therapeutics Trading Down 8.9 %

TVTX traded down $1.76 during mid-day trading on Monday, hitting $17.92. 2,577,321 shares of the stock were exchanged, compared to its average volume of 1,481,836. The firm's fifty day moving average is $20.75 and its two-hundred day moving average is $18.57. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $25.29. The company has a market cap of $1.59 billion, a PE ratio of -4.37 and a beta of 0.75. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The business had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. Equities analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.